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Genome-wide association studies have identified SNPs near ZNF365 at 10q21.2 that are associated with both breast cancer risk and
mammographic density. To identify the most likely causal SNPs, we fine mapped the association signal by genotyping 428 SNPs across
the region in 89,050 European and 12,893 Asian case and control subjects from the Breast Cancer Association Consortium.We identified
four independent sets of correlated, highly trait-associated variants (iCHAVs), three of which were located within ZNF365. The most
strongly risk-associated SNP, rs10995201 in iCHAV1, showed clear evidence of association with both estrogen receptor (ER)-positive
(OR ¼ 0.85 [0.82–0.88]) and ER-negative (OR ¼ 0.87 [0.82–0.91]) disease, and was also the SNP most strongly associated with percent
mammographic density. iCHAV2 (lead SNP, chr10: 64,258,684:D) and iCHAV3 (lead SNP, rs7922449) were also associated with ER-pos-
itive (OR ¼ 0.93 [0.91–0.95] and OR ¼ 1.06 [1.03–1.09]) and ER-negative (OR ¼ 0.95 [0.91–0.98] and OR ¼ 1.08 [1.04–1.13]) disease.
There was weaker evidence for iCHAV4, located 50 of ADO, associated only with ER-positive breast cancer (OR ¼ 0.93 [0.90–0.96]).
We found 12, 17, 18, and 2 candidate causal SNPs for breast cancer in iCHAVs 1–4, respectively. Chromosome conformation capture
analysis showed that iCHAV2 interacts with the ZNF365 andNRBF2 (more than 600 kb away) promoters in normal and cancerous breast
epithelial cells. Luciferase assays did not identify SNPs that affect transactivation of ZNF365, but identified a protective haplotype in
iCHAV2, associated with silencing of the NRBF2 promoter, implicating this gene in the etiology of breast cancer.Introduction
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Genetic Mapping
Tagging Strategy for the Fine-Scale Mapping
We identified the fine-mapping region by taking the furthest
SNPs upstream and downstream with minor allele frequency
(MAF) > 2% and detectable correlation (r2 > 0.1) with
rs10995190, based on the 1000Genomes Project European popula-
tion (March 2010 Pilot version; data from 60 CEU individuals). We
also selected SNPs that tagged all remaining SNPs in the 560 kb in-
terval with r2> 0.9.With this strategy, we selected for inclusion on
the iCOGS array (see below) a total of 440 SNPs, between positions
64205327 and 64765654 (NCBI build 37 assembly), that had an
Illumina designability score (DS) above 0.9. Of these, 428 were
successfully genotyped on the iCOGS array and passed QC filters.
iCOGS Genotyping and Imputation
Case and control samples were drawn from 50 studies partici-
pating in the BCAC, of which 41 were from populations of pre-
dominantly European ancestry and 9 from populations of Asian
ancestry, as described previously.5 We performed iCOGS genotyp-
ing in four centers, as part of the Collaborative Oncological Gene-
Environment Study (COGS). All BCAC studies were approved by
the relevant local ethics committees, as described previously,5
and proper informed consent was obtained from all participants.
We used the genotype data from the 428 SNPs that passed quality
control to impute genotypes at all additional known SNPs in the
interval, using IMPUTE v.2.0 (IMPUTE2) and the 1000 Genomes
Project data (March 2012 version) as a reference panel.12 Rather
than preselecting a reference population, we followed the
approach of Howie et al.13 and used a multi-population reference
panel. IMPUTE2 was applied with default parameters and effective
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Mammographic Density
Mammographic density measurements were available for 6,886
women from nine BCAC studies that were also part of the Marker
Of DEnsity (MODE) consortium6 and DENSNP consortium14
(Table S1). Covariate data were obtained through self-adminis-
tered postal questionnaires, in-person interviews, or telephone
interviews, and anthropometric variables were self-reported or
measured by trained staff (Table S2 of Vachon et al.14). Seven
studies estimated density (absolute and percent dense area) with
the CUMULUS program,15 and two of the studies, the BBCC and
NBCS studies, used the Madena software.16
Statistical Analysis
For each SNP, we estimated a per-allele log-odds ratio (OR) and
standard error using logistic regression, including principal com-
ponents and per-study fixed-effects to adjust for study-specific
differences in allele frequency, as described previously.5 Analyses
were carried out separately for Europeans and Asians. We esti-
mated genetic main effects for ER-positive and ER-negative
breast cancer using logistic regression and restricting the cases
to a specific subtype. We evaluated heterogeneity of association
by tumor subtype in a case-only analysis, treating subtype status
as the dependent variable. We derived the p values for associa-
tion by means of a likelihood-ratio test (one degree of freedom);
all tests were two-sided. To identify the most parsimonious
model, we identified all SNPs with p < 104 and MAF R 2%
in the single SNP analysis and included these in forward selec-
tion regression analyses, utilizing the step function in R with
penalty term set to 10.17 To account for uncertainty in the
data resulting from the imputation process, we conducted
analysis by regressing on the allele dosage for each genotype.
We estimated haplotype-specific ORs using an EM algorithm
implemented in the haplo.stats package in R. For this analysis
we used the most probable genotypes and included study and
principal components as covariates. We grouped haplotypes
with a frequency < 0.01 together into one subgroup of rare
haplotypes.
We assessed individual SNP associations with percentage den-
sity (PD), dense area (DA), and non-dense area (nDA) via linear
regression. Because the distributions of estimated PD, DA, and
nDA were positively skewed (skewness ¼ 1.31, 2.32, and 1.02,
respectively), each phenotype was square-root transformed. This
transformation reduces skewness and has previously been shown
to generate variables that are approximately normally distrib-
uted.18 In addition to study and principal components, we
included age, body mass index (BMI), postmenopausal hormone
replacement therapy (HRT), mammographic view, menopausal
status, and case-control status as covariates in each model. Age
and BMI were treated as continuous variables, and use of post-
menopausal hormones at time of mammogram (0, never; 1,
stopped prior to mammogram date; 2, current use at date of
mammogram; 9, unknown), menopausal status at time of
mammogram (0, postmenopausal; 1, premenopausal; 2, perimen-
opausal; 9, unknown), and case-control status were treated as cat-
egorical variables in the regression model. We also included
mammographic view (1, medio-lateral oblique [MLO] view; 2,
craniocaudal [CC] view) and treated it as categorical variable
because it has been shown that the percent density measure-
ments from the MLO view are systematically lower than those
from the CC view.9 The mean percentage density across all
studies was 17 from the MLO view as compared to 25 from the
CC view.ThExpression Quantitative Trait Locus Analysis
We examined the associations of germline-genotyped and
-imputed SNPs within 1 Mb of the risk region with the expression
levels of all genes within 1Mb, up- and downstream, of the SNP in
question (including ADO [MIM: 611392], ARID5B [MIM: 608538],
c10orf107, EGR2 [MIM: 129010], JMJD1C [MIM: 604503], JMJD1C-
AS1, REEP3 [MIM: 609348], RTKN2 [MIM: 113705], and ZNF365)
in normal breast, adjacent normal, and breast cancerous tissue
from the following four cohorts. Normal breast I (NBI; n ¼ 116)
is comprised of women of European descent ascertained through
multiple Norwegian hospitals. Gene expression data for the
majority of women were derived from normal breast tissue in
women who had not been affected with breast cancer; data for
ten women were derived from normal tissue adjacent to a tumor.
Genotyping was performed with the iCOGS SNP array, and gene
expression levels were measured with the Agilent 44K array.18,19
NBII (n ¼ 93) is the European subset of the TCGA study, for
whom expression data were available from normal tissue adjacent
to a tumor. Germline genotype data from Affymetrix SNP 6 array,
processed through Birdseed, were obtained from TCGA dbGAP
data portal.20 Gene expression levels were assayed by RNA
sequencing, RSEM (RNaseq by Expectation-Maximization21)
normalized per gene, as obtained from the TCGA consortium.20
The data were log2 transformed, and unexpressed genes were
excluded prior to eQTL analysis. Breast carcinomas I (BCI; n ¼
241) is a series of women of European ancestry diagnosed with
breast cancer and recruited throughmultiple Norwegian hospitals.
Genotypes were obtained with the iCOGS SNP array, and mRNA
expression data were from the Agilent 44K array.22 BCII (n ¼
765) is the TCGA breast cancer cohort; all non-European samples
(as determined by clustering and PCA) were excluded from this
analysis.20 The genotyping platform was Affymetrix SNP 6, and
gene expression data, for the breast tumors, was derived from
RNA sequencing analysis, in a similar manner to NBII. There is
no overlap between women recruited to each of these studies.
In addition, we examined all the genotyped or imputed SNPs
used in the risk analysis for association with expression of nine
genes (ADO, ARID5B, c10orf107, EGR2, JMJD1C, NRBF2, REEP3,
RTNK2, and ZNF365, represented by 14 expression probes) in
the 1 Mb region on either side of the fine-mapping interval, using
data from normal tissue in patients from METABRIC. METABRIC
(n ¼ 135) comprises normal tissues adjacent to the tumors from
breast cancer patients of genetically confirmed European ancestry
from the Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) study.23 The samples were assayed
with the Illumina HT-12 v3 microarray. Matched germline SNP
genotypes were available from the Affymetrix SNP 6.0 platform.
For all cohorts, the genotyping data were processed as follows:
SNPs with call rates < 0.95 or minor allele frequencies < 0.05
were excluded, as were SNPs out of Hardy-Weinberg equilibrium
with p < 106. All samples with a call rate below 80% were
excluded. Identity by state was computed with the R GenABEL
package,24 and closely related samples with IBS > 0.95 were
removed. The SNP and sample filtration criteria were applied
iteratively until all samples and SNPs met the stated thresholds.
In total, 489 samples and 662,521 SNPs passed were kept in the
analysis. Imputation was run on both the iCOGS and Affymetrix6
germline genotype data using the 1000 Genomes Project March
2012 v.3 release as the reference dataset.25 A two-stage imputation
procedure, using SHAPEIT to derive phased genotypes and
IMPUTEv2 to perform the imputation on the phased data, has
been found to significantly reduce the computational burden.26e American Journal of Human Genetics 97, 22–34, July 2, 2015 25
The influence of germline genetic variations on gene expression
was assessed using a linear regression model, as implemented in
the R library eMAP. An additive effect was assumed by modeling
copy number of the rare allele, i.e., 0, 1, or 2, for a given genotype.
Only relationships in cis, i.e., where the SNP resided less than 1Mb
up or down from the center of the transcript, were investigated.
Correction for multiple testing was performed using the false
discovery rate (FDR) as implemented in the p.adjust function
in R. Only FDR-adjusted, significant p values are reported in the
Results section of the paper. Genotyping quality control and
imputation for the METABRIC data are described in Guo et al.27
For the METABRIC data, association between genotype and
expression was tested by linear regression with FDR control as
implemented in the MatrixEQTL package in R. We also conducted
eQTL haplotype analysis in NBI and BCII which had been
genotyped on iCOGS. The correlations with expression for the
haplotypes residing in the four iCHAVs were estimated using the
haplo.score function implemented in the R library haplo.stats,
assuming a Gaussian distribution for the expression data.
Cell Lines
Normal breast epithelial cell lines MCF10A and Bre80 were
grown in DMEM/F12 media supplemented with 5% horse serum,
10 mg/ml insulin, 0.5 mg/ml hydrocortisone, 20 ng/ml EGF,
100 ng/ml cholera toxin, and antibiotics. The MCF7 breast cancer
cell line was grown in DMEMmedia supplemented with 10% fetal
bovine serum, 10 mg/ml insulin, sodium pyruvate, and antibiotics.
All cell lines were routinely tested for Mycoplasma and profiled
with short tandem repeats to confirm their identity.
Chromatin Conformation Capture
Cross-linked DNA from the above cell lines was digested with
EcoRI to generate chromatin conformation capture (3C) libraries
as previously described.17 3C interactions were quantitated by
real-time PCR, on at least two independent 3C libraries, using
primers designed against the EcoRI restriction fragments across
the 10q21.2 locus. Interactions were quantified in triplicate. The
primers are listed in Table S2. Primer efficiencies were calculated
using an artificial library of ligation products generated from two
BAC clones (RP11-629KB and RP11-1021P21) that spanned the
10q21 locus and NRBF2. 3C interaction products were visualized
by gel electrophoresis, gel purified, and sequenced to verify the
3C product.
In Silico Analysis
Genomic regions encompassing independent sets of correlated,
highly trait-associated variants (iCHAVs) were examined for po-
tential regulatory signals by overlaying epigenetic marks derived
from ENCODE data using the UCSC Genome Browser. Tracks
representing potential regulatory signals marked by DNaseI hyper-
sensitivity, H3K4me1, H3K4me3, and H3K27ac histone modifica-
tion, and transcription factor binding sites were obtained for
the normal mammary cell types, humanmammary epithelial cells
(HMECs) and human mammary fibroblasts (HMFs), and two
breast cancer cell lines, MCF7 and T47D. SNPs in each iCHAV
were examined for potential functional consequences using
HaploReg v.228 and RegulomeDB.29
Plasmid Generation
A 1,287-bp fragment containing the ZNF365 promoter and a
1,163-bp fragment containing the NRBF2 promoter were cloned26 The American Journal of Human Genetics 97, 22–34, July 2, 2015into the pGL3 basic luciferase reporter. Using a sample heterozy-
gous for rs2393886 as template, we then generated 1,875-bp
PCR fragments containing part of iCHAV2 using PCR primers
modified with BamH1 and Sal1 and cloned each haplotype into
both the ZNF365 and NRBF2 promoter constructs. PCR primers
are listed in Table S2.
Reporter Assays
Bre80, MCF10A, and MCF7 cells were transiently transfected with
equimolar amounts of luciferase reporter constructs using Renilla
luciferase as an internal control reporter. Luciferase activity was
measured 24 hr after transfection using Dual-Glo Luciferase
(Promega). To correct for any differences in transfection efficiency
or cell lysate preparation, Firefly luciferase activity was normalized
to Renilla luciferase, and the activity of each construct was
measured relative to the promoter alone construct, which had a
defined activity of 1. Association was assessed by log transforming
the data and performing two-way ANOVA, followed by Dunnett’s
multiple comparisons test; for ease of interpretation, values were
back transformed to the original scale for the graphs.Results
We successfully genotyped 428 SNPs across the 560-kb
fine-mapping region in 46,450 case subjects and 42,600
control subjects from 41 case-control studies in popula-
tions of European ancestry, and in 6,269 case subjects
and 6,624 control subjects from 9 case-control studies
of Asian ancestry.5 We imputed genotypes for 3,409
SNPs in the interval in the European studies, at imputation
r2 > 0.3 and MAF R 1%, using known genotypes in com-
bination with data from the 1000 Genomes Project refer-
ence panel. Based on data from the European studies, 87
genotyped or imputed SNPs were convincingly associated
with overall risk of breast cancer (p values 107 to 1029;
Figure 1). The results for all SNPs in the interval with an
association p value < 1 3 103 for overall breast cancer
risk (382 SNPs) are presented in Table S3.
Among the genotyped SNPs, the strongest evidence of
associationwith overall breast cancer risk among Europeans
was for rs10995194 (OR [95% CI] ¼ 0.86 [0.84–0.88],
p ¼ 3.77 3 1029). This SNP lies within intron 4 of
ZNF365 and is strongly correlated with the original GWAS
hit rs10995190 (r2 ¼ 0.99). Analysis of the imputed SNPs
identified two markers with slightly stronger associations:
the most significantly associated marker was rs10995201
(OR ¼ 0.85 [0.83–0.88], p ¼ 1.05 3 1029), which is also
strongly correlated with rs10995194 (r2 ¼ 0.94).
Multiple Independent Signals at 10q21.2
To determine whether there were additional independent
signals of association at the locus, we included in a forward
stepwise regression model 230 SNPs with MAF R 2% that
displayed evidence of association with overall breast
cancer risk at p < 104. The most parsimonious model
included four independent SNPs that mark four iCHAVs
(Figure 1; Table 1). These were as follows: iCHAV1,
rs10995201 (OR ¼ 0.85 [0.83–0.88], p ¼ 1.05 3 1029;
Figure 1. Association Results for Overall
Breast Cancer Risk
Directly genotyped SNPs are shown as
filled black circles, and imputed SNPs
(r2 > 0.3, MAF > 0.02) are shown as open
red circles, plotted as the negative log of
the p value against relative position across
the locus.
(A) A schematic of the gene structures
is shown. iCHAVs, encompassing all
SNPs with a likelihood ratio of < 1:100
compared with the most significant SNP,
are labeled and are shown as gray regions.
The pattern of LD for all SNPs from the
1000 Genomes Project CEU population is
shown as a plot of pairwise r2 values using
a greyscale, where white and black signify
r2 ¼ 0 and 1, respectively. The dashed pur-
ple line represents genome-wide signifi-
cance (p < 5 3 108).
(B) iCHAV4 is shown in more detail.conditional p ¼ 4.92 3 1016); iCHAV2, chr10:
64,258,684:D (OR ¼ 0.93 [0.91–0.95], p ¼ 4.24 3 1014;
conditional p ¼ 3.24 3 105); iCHAV3, rs7922449 (OR ¼
1.06 [1.04–1.08], p ¼ 1.68 3 107; conditional p ¼
5.78 3 105); iCHAV4, rs9971363 (OR ¼ 0.94 [0.92–
0.97], p ¼ 6.54 3 105; conditional p ¼ 3.95 3 104)
(Figure 1B). These four SNPs were all imputed, with
IMPUTE2 info-score above 0.85. The strongest pairwise
LD r2 value among the four markers was 0.12 (between
rs10995201 and chr10: 64,258,684:D). Among the
genotyped SNPs, the top SNP correlated with the lead
iCHAV1 SNP was rs10995194 (OR ¼ 0.86 [0.84–0.88],
p ¼ 3.77 3 1029, r2 ¼ 0.94), with the lead iCHAV2 SNP
was rs2393886 (OR ¼ 0.93 [0.91–0.95], p ¼ 4.50 3 1014,
r2 ¼ 0.99), with the lead iCHAV3 SNP was rs4746428
(OR ¼ 1.06 [1.04–1.08], p ¼ 3.24 3 108, r2 ¼ 0.68), and
with the lead iCHAV4 SNP was rs10995312 (OR ¼ 0.95
[0.92–0.97], p ¼ 1.38 3 104, r2 ¼ 0.97).
In order to identify the candidate causal SNPs in each
iCHAV for subsequent functional analysis, we calculated
the likelihood ratio of each SNP relative to the best inde-
pendent signal with which it was correlated (r2> 0.6), after
adjusting for the lead SNP of preceding iCHAV(s). SNPs
with a relative likelihood ratio of <1:100 compared with
the most significant SNP for each iCHAV were excluded
from consideration as being potentially causative.16,30
Eleven SNPs had a relative likelihood ratio of >1:100
compared with the most significant SNP (rs10995201)
and hence could not be excluded as causative for theThe American Journal of Hlead signal—these SNPs were all
strongly correlated with rs10995201
and span an interval of 31.2 kb
(iCHAV1, Figure 1, Table S4). A 12th
SNP, a single base insertion chr10:
64,291,099, was excluded at this
threshold, but not strongly so (likeli-
hood ratio ~1:600); all other SNPscould be clearly excluded (likelihood ratios < 1:1012).
After adjustment for lead SNP of iCHAV1, we identified
16 strongly correlated SNPs and with a likelihood
ratio >1:100 relative to the lead SNP in iCHAV2 (chr10:
64,258,684:D); these SNPs span an interval of 25 kb
(iCHAV2, Figure 1, Table S5). SNP rs16917302 (OR ¼ 0.96
[0.93–0.99], p ¼ 1.03 3 102), reported by Couch et al.,31
lies within the region that iCHAV2 spans. However,
rs16917302 is only weakly correlated with the lead SNP
(r2 ¼ 0.12) in iCHAV2. After adjusting for the effects of
lead SNPs of iCHAV1 and iCHAV2, 17 highly correlated
SNPs had a relative likelihood >1:100 compared to
rs7922449 (iCHAV3, Figure 1, Table S6) and span an inter-
val of 29.1 kb. Finally, only one other SNP, rs7090365, had
a relative likelihood of >1:100 with respect to rs9971363
the lead SNP of iCHAV4, after adjusting for the lead SNPs
in iCHAVs 1–3 (Figure 1, Table S7). iCHAVs 1, 2, and 3 all
lie within ZNF365. The SNPs in iCHAV1 and iCHAV3
span regions that physically overlap, whereas the SNPs in
iCHAV2 lie telomeric to iCHAV1 and iCHAV3. iCHAV4
lies 50 of ADO, which encodes 2-aminoethanethiol dioxy-
genase (Figure 1).
Association with Breast Cancer Subtypes
Based on data from European studies, 31 genotyped
SNPs and 14 imputed SNPs were associated with risk of
ER-positive breast cancer (p values 107 to 1023). The
most strongly associated SNP for overall breast cancer
(rs10995201) was also the most strongly associated SNPuman Genetics 97, 22–34, July 2, 2015 27
Table 1. Four iCHAVs at 10q21.2 Associated with Breast Cancer Risk or Mammographic Density Phenotype in Europeans
iCHAV1 iCHAV2 iCHAV3 iCHAV4
rs10995201a chr10: 64,258,684:Da rs7922449a rs9971363a
p Valueb OR (95% CI)b p Valueb OR (95% CI)b p Valueb OR (95% CI)b p Valueb OR (95% CI)b
Overall 1.05 3 1029 0.85 (0.83–0.88) 4.24 3 1014 0.93 (0.91–0.95) 1.68 3 107 1.06 (1.04–1.08) 6.54 3 105 0.94 (0.92–0.97)
ERþ 2.51 3 1023 0.85 (0.82–0.88) 8.01 3 1011 0.93 (0.91–0.95) 6.70 3 106 1.06 (1.03–1.09) 1.26 3 105 0.93 (0.90–0.96)
ER 9.60 3 108 0.87 (0.82–0.91) 0.0055 0.95 (0.91–0.98) 0.000268 1.08 (1.04–1.13) 0.776 0.99 (0.94–1.05)
p Valuec b (SE)c p Valuec b (SE)c p Valuec b (SE)c p Valuec b (SE)c
Density area 1.45 3 107 0.25 (0.05) 0.00555 0.09 (0.03) 0.308 0.04 (0.04) 0.634 0.02 (0.05)
Percent density 1.32 3 105 0.15 (0.04) 0.00155 0.08 (0.02) 0.634 0.01 (0.03) 0.629 0.02 (0.04)
SNPd p Valued Infoe SNPd p Valued Infoe SNPd p Valued Infoe SNPd p Valued Infoe
rs10995181f 5.07 3 1028 1 rs4489633f 1.45 3 109 0.96 rs1878253f 6.54 3 108 1 rs9971363a,g 6.54 3 105 0.97
rs10995182g 3.42 3 1028 0.92 rs4282885f 8.51 3 1010 0.99 rs1914200f 1.03 3 107 1 rs7090365g 6.59 3 105 0.97
rs10995187f 6.66 3 1029 1 rs10995173f 3.89 3 1010 1 rs10740081g 9.17 3 108 0.99
rs4746419f 4.43 3 1029 1 rs10822012g 3.93 3 1010 0.99 rs10761639g 1.01 3 107 0.98
rs34511355f 6.22 3 1029 1 rs10761637g 3.92 3 1010 0.99 rs7901318g 7.26 3 108 0.98
rs10995189f 6.04 3 1029 1 rs12098307g 4.16 3 1010 0.99 rs2393894g 5.95 3 108 0.97
rs10995190f 5.61 3 1029 1 rs10822013f 8.81 3 1011 1 rs7922449a,g 1.68 3 107 0.86
rs10995191f 6.04 3 1029 1 rs10509168f 2.22 3 1013 1 rs10995196g 2.70 3 108 0.98
rs11524313g 4.16 3 1029 0.97 rs10995176g 7.17 3 1014 0.99 rs4746428f 3.24 3 108 1
rs10995193g 3.67 3 1029 0.99 c10_pos64258017f 1.03 3 1013 1 chr10: 64,293,571:Dg 1.94 3 108 0.88
rs10995194f 3.77 3 1029 1 rs2393886f 4.50 3 1014 1 rs9633558g 2.62 3 108 0.99
rs10995201a,g 1.05 3 1029 0.95 chr10: 64,258,684:Da,g 4.24 3 1014 0.98 rs7915519g 2.63 3 108 0.99
chr10: 64,258,692:Dg 8.51 3 1013 0.86 rs6479823g 2.66 3 108 0.99
rs12243471f 4.00 3 1010 0.99 rs1914182g 2.62 3 108 0.99
rs12245332f 3.95 3 1010 1 rs10822017g 2.07 3 108 0.99
rs2393887f 6.94 3 1010 1 rs7901573g 2.93 3 108 0.99
rs4746409f 3.06 3 1012 1 rs12258134g 2.94 3 108 0.99
rs1949356f 3.61 3 108 1
aLead SNP for each iCHAV.
bp value, odds ratio (OR), and 95% confidence interval (CI) for association with overall breast cancer risk, estrogen-positive (ERþ), and estrogen-negative (ER) disease.
cp value, beta, and standard error (SE) for association with percentage density, dense area.
dSNPs correlated (r2 > 0.6) with a likelihood ratio of >1:100 with respect to overall risk association relative to lead SNP of each iCHAV and corresponding p value for association with overall breast cancer risk.
eIMPUTE2 info score.
fGenotyped marker.
gImputed marker.
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for ER-positive disease (OR ¼ 0.85 [0.82–0.88], p ¼ 2.51 3
1023) and had a similar association for ER-negative disease
(OR ¼ 0.87 [0.82–0.91], p ¼ 9.60 3 1008, pheterogeneity ¼
0.34) (Table 1, Figures S1 and S2). The most strongly asso-
ciated, well-imputed SNP (IMPUTE2 info-score > 0.9) for
ER-negative disease was rs10995182 (OR ¼ 0.85 [0.8–0.9],
p ¼ 6.68 3 108), another SNP within iCHAV1 strongly
correlated with rs10995201. Thus, the results indicate
that susceptibility SNPs in iCHAV1 confer similar relative
risks for ER-positive and ER-negative disease. Similarly,
the lead SNPs in iCHAVs 2 and 3 showed similar associa-
tions for ER-positive and ER-negative disease (ORERþ ¼
0.96 [0.94–0.98], pERþ ¼ 8.77 3 1004, ORER ¼ 0.98
[0.94–1.02], pER ¼ 0.309, pheterogeneity ¼ 0.44 for chr10:
64,258,684:D adjusted for iCHAV1, ORERþ ¼ 1.04 [1.02–
1.07], pERþ ¼ 1.54 3 1003, ORER ¼ 1.07 [1.02–1.11],
pER ¼ 4.36 3 1003, pheterogeneity ¼ 0.44 for rs7922449
adjusted for iCHAVs 1 and 2). However, the lead SNP
in iCHAV4 showed no association with ER-negative disease
(ORERþ ¼ 0.93 [0.90–0.97], pERþ ¼ 7.72 3 1005, ORER ¼
1.00 [0.94–1.05], pER ¼ 0.862, pheterogeneity ¼ 0.016 for
rs9971363 adjusted for iCHAVs 1, 2, and 3).
To determine whether there were additional subtype-
specific signals of association, we included all SNPs display-
ing evidence for association with ER-positive disease (222
SNPs, p < 104 and MAF R 2%) and ER-negative disease
(19 SNPs, p < 104 and MAF R 2%) in separate forward
stepwise regression models. For ER-positive disease,
two iCHAVs were identified: iCHAV1-ERþ rs10995201
(OR ¼ 0.85 [0.83–0.88], p ¼ 2.51 3 1023; conditional
p ¼ 1.65 3 1018) in iCHAV1 and iCHAV2-ERþ chr10:
64,258,684:D (OR ¼ 0.93 [0.91–0.95], p ¼ 8.01 3 1011;
conditional p ¼ 2.59 3 1005) in iCHAV2.
Breast Cancer Risk Associations in Asian Studies
The top associated marker among Asians was the geno-
typed SNP rs7914770 (OR ¼ 0.93 [0.89–0.98], p ¼ 0.006).
This SNP, which lies between iCHAV1 and iCHAV4,
as defined in analysis of the European population, was
not associated with overall breast cancer risk among Euro-
peans (OR ¼ 1.01 [0.98–1.03], p ¼ 0.534; Table S8). The
most strongly associated genotyped SNP in Europeans,
rs10995194 in iCHAV1, showed a borderline association
with breast cancer risk in Asians, but in the opposite direc-
tion (Asians: OR ¼ 1.18 [1.00–1.39], p ¼ 0.04; Europeans:
OR ¼ 0.86 [0.84–0.88], p ¼ 3.77 3 1029). The minor (C)
allele of rs10995194 (MAF ¼ 0.15) and the other iCHAV1
SNPs were much rarer in Asians (MAF ¼ 0.02), but the
ORs estimates nevertheless differed significantly (p ¼
104). In iCHAV2, the most strongly associated genotyped
SNP in Europeans, rs2393886 (OR ¼ 0.93, MAF ¼ 0.47 for
the A allele), was also associated with risk in Asians;
however, in contrast to iCHAV1, the effects were in the
same direction and of comparable magnitude (OR ¼ 0.95
[0.90–1.00], p ¼ 0.04, allele frequency 0.51 for the A allele
in Asians). In this iCHAV the most strongly associated SNP
in Asians was rs4746409 (OR ¼ 1.06 [1.00–1.11], p¼ 0.03),Thbut this is strongly correlated with the lead SNP rs2393886
(r2¼ 0.88). SNP rs10822013 within iCHAV2, recently iden-
tified by Cai et al. in an Asian GWAS,7 was more weakly
associated with risk in Asians in our data (OR ¼ 0.96
[0.90–1.10], p ¼ 0.07). None of the genotyped markers in
iCHAV3 or iCHAV4 that were significant in Europeans
showed association with overall breast cancer risk in the
Asian population.
Haplotype Analysis
We conducted haplotype analysis using the most probable
genotype for the imputed lead SNPs in each of the iCHAVs.
We grouped haplotypes with a frequency < 0.01 into one
(rare) group. The haplo.score procedure estimated 11 hap-
lotypes with non-zero frequencies for all three phenotypes
(overall, ERþ, and ER risk) (Table S9). The most significant
association was observed for haplotype H6, carrying the
rare allele of the lead SNPs of iCHAV1 and iCHAV2:
OR ¼ 0.86 (0.82–0.90), p ¼ 8.52 3 1010. Consistent
with the regression analyses, the three haplotypes (H6,
H14, H5) carrying the rare allele of the iCHAV1 SNP
rs10995201 were all associated with a similar, reduced
breast cancer risk. Three other haplotypes, all carrying
the rare allele of the iCHAV2 SNP, chr10: 64,258,684:D,
were also associated with a reduced risk, relative to the
baseline haplotype, consistent with an independent effect
of iCHAV2.
Association with Mammographic Density Phenotypes
Multiple linear regression was used to investigate the
association between mammographic density phenotypes
(PD, percent density; DA, dense area; nDA, non-dense
area) and genotypes after adjustment for other covariates.
Among the three density phenotypes, the strongest associ-
ations were observed with DA. The strongest association
with DA and PD was seen with the lead SNP of iCHAV1,
rs10995201 (b (SE) ¼ 0.25 [0.05], p ¼ 1.45 3 1007 for
DA, b (SE) ¼ 0.15 [0.04], p ¼ 1.32 3 1005 for PD; Tables
S10, S11; Figures S3 and S4). After adjusting for the lead
SNP in iCHAV1, no SNPs in iCHAV2 were associated with
any of the density phenotypes at p< 0.01 (Table S12); simi-
larly, none of the iCHAV3 or iCHAV4 SNPs were associated
with density phenotypes (Tables S13 and S14). The stron-
gest association with nDA was seen with imputed marker
rs224303 about 33 kb away from iCHAV4 (Figure S5),
which was not associated with overall risk of breast cancer
(p ¼ 0.745).
To assess the extent to which the observed association
with breast cancer risk might be mediated through a
mammographic density phenotype, we estimated the asso-
ciation with breast cancer risk before and after adjustment
for PD, DA, or nDA in a pooled analysis of the 2,379 breast
cancer case subjects and 4,507 control subjects for whom
density measurements were available. The association be-
tween lead iCHAV1 SNP rs10995201 (i.e., the only iCHAV
for which an association with mammographic density had
been identified) and breast cancer in this subset (OR¼ 0.87e American Journal of Human Genetics 97, 22–34, July 2, 2015 29
Figure 2. Chromatin Interactions with
the ZNF365 and NRBF2 Promoters at the
10q21.2 Locus
(A) 10q21.2 locus showing the distances
from iCHAVs 1–4 and the nearest genes.
(B–G) Chromatin interaction frequencies
were plotted at the corresponding chromo-
somal position for MCF7 (B and E),
MCF10A (C and F), and Bre80 (D and G)
for the ZNF365 and NRBF2 promoters,
respectively. iCHAV2 is marked in green,
iCHAV1 (which physically overlaps
iCHAV3) in blue, and iCHAV3 in red.
Representative graphs are shown (N ¼ 3)
and error bars denote SD.[0.77–0.98], p ¼ 0.02) was similar to that in the complete
BCAC set and was only slightly attenuated after adjust-
ment for PD (OR ¼ 0.88 [0.78–1.00], p ¼ 0.05) or DA
(OR ¼ 0.89 [0.79–1.01], p ¼ 0.06) (Table S15).
eQTL Analysis
We analyzed 2,238, 5,122, 2,250, 5,211, and 3,814 SNPs
in NBI, NBII, BCI, BCII, and METABRIC, respectively, for
association with the expression levels of all genes within
1 Mb, up- and downstream, of the SNP in question. Signif-
icant eQTL associations were observed for both normal
breast and tumors. Multiple SNPs within the fine mapping
region associated with expression of c10orf107 in the
NBII cohort (strongest association, chr10: 63,427,159:D,
which is not a candidate causal risk SNP; FDR-adjusted
p ¼ 6.1 3 105 and r2 ¼ 0.325). For the BCI cohort, multi-
ple eQTLs were found for both c10orf107 and RTKN2
(strongest associations chr10: 63,427,159:D, FDR-adjusted
p ¼ 4.3 3 106 and r2 ¼ 0.15, and rs870988, FDR-adjusted
p ¼ 1.4 3 105 and r2 ¼ 0.13, respectively). In BCII we
observed multiple eQTLs for three different genes,
c10orf107, EGR2, and ADO (rs12781009, FDR-adjusted30 The American Journal of Human Genetics 97, 22–34, July 2, 2015p ¼ 5.6 3 109 and r2 ¼ 0.066;
rs34632941, FDR-adjusted p ¼ 0.02
and r2 ¼ 0.02; and rs224045, FDR-
adjusted p ¼ 0.02 and r2 ¼ 0.02,
respectively). No significant associa-
tions with expression were found for
NBI or METABRIC, and there were
no significant associations between
the putative causal SNPs in iCHAVs
1–4 and expression of any of the
genes analyzed in the region in any
study (Tables S16 and S17). Signifi-
cant associations (without correction
for multiple testing) were found be-
tween haplotypes of iCHAV1 and
NRBF2 in NBI and BCI (p ¼ 0.005
and p ¼ 0.042, respectively) and be-
tween haplotypes of iCHAV2 and
NRBF2 in NBI (p ¼ 0.011). In addi-
tion, we found associations betweenhaplotypes of iCHAV1 and REEP3, EGR2, and RTKN2
(p ¼ 0.011–0.049), haplotypes of iCHAV2 and RTKN2
(p ¼ 0.012), haplotypes of iCHAV3 and REEP3, JMJD1C,
ARID5B, ADO, RTKN2, and TMEM26 (p ¼ 0.001–0.036),
and haplotypes of iCHAV4 and ARID5B (p ¼ 0.012) in
either NBI or BCI, but not both.
Chromosome Conformation Capture Analyses
Identify ZNF365 and NRBF2 as Target Genes
We performed 3C experiments to determine whether there
were any chromatin interactions between the ZNF365 and
NRBF2 promoters and iCHAVs 1, 2, and 3. We identified
significant interactions between iCHAV2 at the 10q21.2
locus and both promoter regions in the breast cancer cell
line, MCF7, and in two normal breast cell lines, MCF10A
and Bre80 (Figures 2 and S6). No reproducible interactions
were detected between iCHAVs 1 or 3 and ZNF365 and
NRBF2 in the cell lines analyzed. Although we did observe
some possible interactions in MCF7 and MCF10A between
different parts of iCHAV 1/3 and the promoters of both
ZNF365 and NRBF2, they were not reproducible (Figures
2 and S6).
Figure 3. Chromatin Marks in Breast Cells in iCHAVs at 10q21.2
The region encompassing 1 Mb at 10q21.2 is shown in (A). Candidate causal SNPs lying within iCHAVs 1–4 are shown as tick marks in
matching colors to iCHAVs. DNaseI hypersensitive sites found in mammary cell types from ENCODE are depicted under the gene sche-
matics. iCHAV2 is shown in (B). ENCODE tracks are shown for mammary DNaseI HS, histone modification ChIP-seq, and transcription
factor ChIP-seq. The cloned PRE2 region for the iCHAV2 reporter construct is marked.Identification of a Putative Regulatory Region within
iCHAV2 Regulating both ZNF365 and NRBF2
We used available ENCODE ChIP-seq data to identify puta-
tive regulatory elements (PREs) within iCHAV2 (Figure 3A).
We identified two PREs (PRE1 and PRE2), as defined by
DNaseI hypersensitivity sites (indicative of regions of
open chromatin), in several normal and cancer breast cell
lines, and H3K4me1 and H3K4me2 histone modifications
in HMECs (Figure 3B). PRE1 lies in a complex repetitive
region and we were unable to clone and analyze this
region. However, 6 (chr10: 64,258,684:D, rs2393886,
rs10995176, c10_pos64258017, rs10509168, and chr10:
64,258,692:D) of the 17 candidate causal SNPs lie within
PRE2 (Figure 3B). We examined the regulatory capability
of PRE2, combined with the effect of the protective haplo-
type, using luciferase constructs containing the ZNF365
or NRBF2 promoters. Inclusion of the reference haplotype
of iCHAV2 did not significantly alter the effect of the
NRBF2 promoter in Bre80 cells. However, the construct
containing the protective haplotype acted as a silencer
relative to the iCHAV2 reference allele (p ¼ 0.003; Figures
4A and S7). A similar trend was seen in MCF7 cells (p ¼
0.029; Figure 4C). Although constructs containing the
ZNF365 promoter showed a trend reducing its activity
with the reference haplotype of iCHAV2, this was signifi-
cant only in MCF7 cells (Figures 4B and 4D). Similarly,
inclusion of the protective haplotype reduced the
ZNF365 promoter activity but had no effect relative to
the iCHAV2 reference haplotype in either Bre80 or MCF7
cells (Figures 4B and 4D).ThDiscussion
Our large combined dataset provides clear confirmation of
a susceptibility locus for breast cancer at 10q21.2 for breast
cancer as originally reported by Turnbull et al.4 and for
mammographic density as reported by Lindstro¨m et al.9
Multiple regression and haplotype analyses showed clear
evidence of at least two, and potentially four, independent
susceptibility loci in this region in Europeans. The most
strongly associated SNP, rs10995201 in iCHAV1, showed
clear evidence of association with both ER-positive and
ER-negative disease, with the ORs being similar, and was
also the SNP most strongly associated with mammo-
graphic density (DA, and hence PD). iCHAV2 (lead SNP,
chr10: 64,258,684) and iCHAV3 (lead SNP, rs7922449)
also appeared to be associated with both ER-positive and
ER-negative disease. Evidence of a fourth iCHAV, associ-
ated only with ER-positive breast cancer, was weaker. In
contrast to the results in Europeans, there was less evi-
dence of association between SNPs at this locus and breast
cancer risk in Asian women. The top associated genotyped
SNP among Asians was rs7914770, which was not associ-
ated with overall breast cancer risk among Europeans.
Furthermore, the lead genotyped SNP in Europeans,
rs10995194, showed borderline evidence of association
with breast cancer in Asians in the opposite direction,
such that the effect sizes were clearly different. There are
several possible explanations for the difference in the
effect of iCHAV1 by ethnicity. The difference might reflect
the differential effect of another SNP, or SNPs, in thee American Journal of Human Genetics 97, 22–34, July 2, 2015 31
Figure 4. Protective Haplotype of iCHAV2 Silences NRBF2 Promoter Activity
Both haplotypes of the iCHAV2 PRE2were cloned upstream ofNRBF2- and ZNF365-promoter-driven luciferase reporters. Cells were tran-
siently transfected with the common (PRE2) and the protective (Prot Hap) haplotype constructs and assayed for luciferase activity 24 hr
later. Results for the NRBF2 and ZNF365 promoters in Bre80 cells are shown in (A) and (B) and results for NRBF2 and ZNF365 promoters
in MCF7 cells are shown in (C) and (D). Error bars denote 95% confidence intervals from three independent experiments performed in
triplicate. p values were determined by two-way ANOVA followed by Dunnett’s multiple comparisons test (**p < 0.01, *p < 0.05) on log
transformed data; for ease of interpretation, back-transformed data have been graphed.10q21.2 region. Alternatively, it might reflect trans-
interactions with SNPs elsewhere in the genome. Larger
studies in Asian populations, both for breast cancer risk
and mammographic density, might help to resolve this
paradox. The SNPs in iCHAV2, however, showed effects
that were consistent between the two populations.
The A allele of rs10995190 in iCHAV1 is associated with
decreased ER-positive and ER-negative breast cancer risk,
as well as with lower percent mammographic density and
reduced dense area. These results are consistent with the
hypothesis that the same causal SNP confers susceptibility
to both mammographic density and breast cancer risk.
However, adjustment for percent density or dense area
caused only a minor attenuation of the association
between breast cancer risk and the lead iCHAV1 SNP. The
implications of this finding are not clear, but it is likely
that percent and absolute mammographic density as
captured by a two-dimensional mammogram, despite be-
ing strong predictors of breast cancer risk, are imperfect
measures of the underlying mechanism that drives breast
cancer risk. Alternatively, it might be that different SNPs
in this iCHAV are acting independently on mammo-
graphic density and breast cancer risk, and through
different mechanisms. We did not observe associations
with mammographic density for breast cancer-associated
SNPs in the other iCHAVs, but the smaller sample size,
and hence lower statistical power, for the mammographic
density analysis mean that more subtle effects in other
iCHAVs would not have been detectable.
As we have reported for the breast cancer loci at 11q1317
and 2q35,32 we did not find any evidence for single
SNP eQTLs for any of the putatively causal SNPs in iCHAVs32 The American Journal of Human Genetics 97, 22–34, July 2, 20151–4 in normal or cancerous breast samples. This might be
because the power of the eQTL studies (n ¼ 93–765) is
limited, or because eQTLs are context dependent and
might be expressed only in certain cell types or in response
to certain stimuli. We have, however, identified a putative
regulatory element in iCHAV2 at the 10q21.2 locus that in-
teracts with both the NRBF2 and ZNF365 promoters in
both normal breast and breast epithelial tumor cells. It is
interesting that we detected haplotype associations with
iCHAV1 and iCHAV2 and NRBF2 expression, but the
significance of these is difficult to interpret given their
modest p values and the fact that these iCHAVs are far
too big to be cloned in their entirety for luciferase assays.
We prioritized the 3C analysis to look for interactions
between iCHAVs 1, 2, and 3 and the promoters of
ZNF365 and NRBF2 because of their function. NRBF2 en-
codes nuclear receptor binding protein 2, an interaction
partner of the peroxisome proliferator-activated receptor
alpha (PPARa), and exhibits a gene activation function in
mammalian cells.33 Furthermore, NRFB2 is thought to
have a role in cell survival in neural progenitor cells34
and to suppress autophagy,35 a process that needs to be
tightly controlled in breast cells during normal develop-
ment, tissue differentiation, and response to stress.36 To
our knowledge, NRBF2 has not previously been implicated
in breast cancer tumorigenesis. Our results suggest that the
haplotype in iCHAV2 associated with reduced risk of breast
cancer is associated with silencing of the NRBF2 promoter.
ZNF365 encodes the zinc finger protein 365, which plays a
critical role in stabilizing fragile sites within the genome
and telomeres37 and maintaining genome stability,38
and is therefore a good candidate for a breast cancer
susceptibility gene. Although we did not observe a differ-
ential effect of the protective haplotype on the ZNF365
promoter in luciferase assays, the protective SNPs might
act through differential looping as we have previously
observed at the 2q35 breast cancer risk locus.32 Alterna-
tively, other candidate causal SNPs in PRE1 or elsewhere
in iCHAV2 might have a differential effect on transactiva-
tion of the ZNF365 promoter. We did not find any
convincing evidence for interactions between iCHAV1/3
and the promoters of ZNF365 or NRBF2 in MCF7,
MCF10A, or Bre80 cells. It is possible that other genes,
such as ADO, which encodes 2-aminoethanethiol dioxyge-
nase, or EGR2 encoding early growth response-2, are the
targets of these iCHAVs, or that their interactions with
ZNF365 or NRBF2 are manifest in different cell types,
such as of the immune system, or only in response to
specific stimuli.
In conclusion, we have found evidence for four sets of
correlated genetic variants (iCHAVs) at 10q21.2 indepen-
dently associated with breast cancer risk, one of which is
also associated with mammographic density. In one of
these iCHAVs, we have identified candidate causal SNPs
that affect expression of NRBF2, which lies more than
600 kb away, suggesting that expression of NRFB2 might
play a role in transformation or progression of transformed
breast cells.Supplemental Data
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